IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1026-1050 out of 1365.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

Public Release: 18-Feb-2016
The EMBO Journal
Doughnut-shaped holes of killer proteins observed for the first time
Spanish and German researchers have successfully seen for the first time the pores, shaped like rings and crescent moons, that the Bax protein perforates in mitochondrial membranes. This advance has been achieved thanks to super-resolution microscopy and may help find the 'holy grail' of cell suicide, a crucial process in preventing cancer.

Contact: SINC
info@agenciasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology

Public Release: 18-Feb-2016
Cancer Discovery
When the immune system promotes tumor growth
The immune system plays an important role in the prevention of cancer. So-called Natural killer cells are innate immune cells and responsible for the elimination of cancerous cells. Researchers from the Vetmeduni Vienna have now discovered that NK cells can switch and promote tumor growth, with STAT5 acting as the key regulator. Drugs targeting STAT5 may therefore boost tumor growth. The study was published in Cancer Discovery.

Contact: Susanna Berger
susanna.berger@vetmeduni.ac.at
43-125-077-1153
University of Veterinary Medicine -- Vienna

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Chemotherapy before chemoradiation shows no survival advantage in head and neck cancer
Results presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona show patients receiving induction chemotherapy rather than chemoradiation live no longer and are less likely to receive definitive course of radiation treatment.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Study links health insurance status and head and neck cancer diagnoses, outcomes
Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
JAMA Oncology
Are improved outcomes after initial implementation of digital breast tomosynthesis sustainable?
A new study of breast cancer screening published online by JAMA Oncology suggests 3-D digital breast tomosynthesis (DBT) outcomes were sustainable with significant reduction in patient recall, increasing cancer cases per recalled patients and a decline in interval cancers.

Contact: Greg Richter
gregory.richter@uphs.upenn.edu
215-614-1937
The JAMA Network Journals

Public Release: 18-Feb-2016
Cell Reports
Study pinpoints driver, potential target in aggressive pediatric leukemia subtype
A University of Colorado Cancer Center study scheduled for Feb. 18, 2016 online publication in the journal Cell Reports models Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL), discovering inactivation of the gene EZH2 as a driver and inroad to a potential therapeutic target in the disease.
National Cancer Institute, National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 18-Feb-2016
Multidisciplinary Head and Neck Cancer Symposium
Cancer-causing gene found in plasma may help predict outcomes for head and neck patients
Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients.
UC Division of Hematology Oncology

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Chemoradiation may increase survival for a subset of elderly head and neck cancer patients
According to University of Colorado Cancer Center research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium, the addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 18-Feb-2016
JAMA Oncology
3-D mammography improves cancer detection and cuts 'call backs' over 3 years
The increased cancer detection and reduced call backs associated with 3-D mammography, also known as Digital Breast Tomosynthesis (DBT), can be maintained years after a patient's first DBT screening with regularly scheduled DBT imaging, according to a JAMA Oncology study published online today from researchers at the Perelman School of Medicine at the University of Pennsylvania.
NIH/National Cancer Institute

Contact: Greg Richter
greg.richter@uphs.upenn.edu
215-614-1937
University of Pennsylvania School of Medicine

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Study determines key recurrence detection time for oropharyngeal cancer
For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
Nature Scientific Reports
New image analytics may offer quick guidance for breast cancer treatment
For women with the most common type of breast cancer, a new way to analyze magnetic resonance images (MRI) data appears to reliably distinguish between patients who would need only hormonal treatment and those who also need chemotherapy. The analysis may provide women diagnosed with estrogen positive-receptor (ER-positive) breast cancer answers far faster than current tests and, due to its expected low cost, open the door to this kind of testing worldwide.
National Science Foundation, NIH/National Institutes of Health's National Cancer Institute, NIHNational Institute of Biomedical Imaging and Bioengineering, NIH/Diabetes and Digestive and Kidney Diseases, Case Comprehensive Cancer Center

Contact: Bill Lubinger
william.lubinger@case.edu
216-368-4443
Case Western Reserve University

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Majority of LAHNC patients use life-altering strategies to cope with costs of treatment
The majority of patients with locally advanced head and neck cancers (LAHNC) rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
Nanotechnology
Kellogg researchers develop new nanoparticle with potential to treat ocular cancer
Researchers at the University of Michigan Kellogg Eye Center are using nanoparticles to kill tumor cells inside the eye.

Contact: Barbara Wylan Sefton
bwsefton@med.umich.edu
734-763-6967
University of Michigan Health System

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Chemoradiation may increase survival for a subset of elderly head and neck cancer patients
The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Study maps molecular signatures of HPV-positive throat cancer patients by smoking status
Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
LGBT Health
Landmark LGBT Cancer Action Plan recommends SOGI data collection
Increased data collection and research are needed to document and understand elevated cancer risk, cancer incidence and prevalence, and cancer screening disparities in LGBT communities, according to the conclusions and recommendations of the 2014 National Summit on Cancer in the LGBT Communities. The white paper produced from the Summit, entitled 'The National LGBT Cancer Action Plan,' is published in LGBT Health.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 17-Feb-2016
Lancet Oncology
Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt
Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. Moffitt Cancer Center, in conjunction with partner institutions, initiated a multicenter phase 1b clinical trial to determine the safety and efficacy of a new drug combination for non-small cell lung cancer that stimulates a patient's immune system to target and kill cancer cells.

Contact: Steve Blanchard
steve.blanchard@moffitt.org
813-745-1718
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 17-Feb-2016
Inorganic Chemistry
Pairing pain medicine with metal ions to battle cancer
Fighting chemoresistant cancer remains a huge challenge that scientists are tackling from as many angles as they can. One alternative approach involves pairing two groups of compounds -- pain medicine and metal ions -- that have individually shown promise as anti-cancer agents. Scientists report in the ACS journal Inorganic Chemistry that combining the two led to new compounds that could destroy drug-resistant cancer cells and leave most normal cells alone in lab tests.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 17-Feb-2016
JAMA Surgery
Use of breast conservation surgery for cancer decreases; high-rate of reoperation
In a study published online by JAMA Surgery, Art Sedrakyan, M.D., Ph.D., of Weill Cornell Medical College, New York, and colleagues examined the use of breast conservation surgery (BCS) in New York State and determined rates of reoperation, procedure choice, and the effect of surgeon experience on the odds of a reoperation 90 days after BCS.

Contact: Jen Gundersen
jeg2034@med.cornell.edu
646-317-7402
The JAMA Network Journals

Public Release: 17-Feb-2016
Southern Surgical Association Annual Meeting
Journal of American College of Surgeons
Chemotherapy preferable to radiotherapy to reduce distant pancreatic cancer recurrences
Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy.

Contact: Devin Rose
pressinquiry@facs.org
312-202-5324
American College of Surgeons

Public Release: 17-Feb-2016
EBioMedicine
New predictor of cancer
Epigenetic age is a new way to measure your biological age. When your biological (epigenetic) age is older than your chronological age, you are at increased risk for getting and dying of cancer, reports a new study. And the bigger the difference between the two ages, the higher your risk of dying of cancer. The research could be used to develop an early detection blood test for cancer.
US Department of Veterans Affairs

Contact: Marla Paul
marla-paul@northwestern.edu
Northwestern University

Public Release: 17-Feb-2016
Obstetrics & Gynecology
Researchers publish on connection between anal cancer, HPV
Researchers at Women & Infants Hospital, a Care New England hospital, recently published the results of a study demonstrating a connection between anal cancer and human papillomavirus infection.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Care New England

Public Release: 17-Feb-2016
Obstetrics & Gynecology
Researchers find marked gender differences in scholarly productivity
The differences between men and women seem to infiltrate yet another aspect of medicine with a study spearheaded at Women & Infants Hospital, a Care New England hospital, indicating that younger female gynecologic oncologists were less productive scholastically and, therefore, poorly represented in the higher academic ranks, than their male contemporaries.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Care New England

Public Release: 17-Feb-2016
Journal of Thoracic Oncology
Autoantibodies may help detect lung cancer earlier
Preliminary research has identified autoantibodies, immune proteins found in the blood specific for one's own proteins, that can potentially detect lung cancer early by distinguishing between smokers with or without lung cancer and also discriminate between lung cancer and low-dose computed tomography (LDCT) detected non-cancerous lung lesions.

Contact: Jeff Wolf
Jeff.Wolf@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 16-Feb-2016
Journal of Adolescent and Young Adult Oncology
What factors affect non-compliance with endocrine therapy among young women with breast cancer?
A new study from Harvard Medical School of young women with hormone receptor-positive (HR+) breast cancer showed that more than half did not believe endocrine therapy was essential, even though it has been proven to reduce recurrence and improve survival. Young women with HR+ breast cancer are at increased risk for recurrence and decreased survival, yet they are also more likely to fail to adhere to endocrine treatment as prescribed, as reported in the study published in Journal of Adolescent and Young Adult Oncology.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Showing releases 1026-1050 out of 1365.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

  Search News Releases

     

 

EurekAlert!